Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019

Autor: Gregory J. Mertz, Qiuying Cheng, Alexandra Yingling, Jay S. Raval, Chunyan Ye, Douglas J Perkins, Timothy Philip Noonan, Nestor Sosa, Steven B. Bradfute, Michelle Harkins, Ivy Hurwitz
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
New Mexico
coronavirus
Blood Donors
medicine.disease_cause
Antibodies
Viral
Immunoglobulin G
Cohort Studies
0302 clinical medicine
Medicine
antibodies
Immunology and Allergy
030212 general & internal medicine
Neutralizing antibody
Coronavirus
Aged
80 and over
biology
Reverse Transcriptase Polymerase Chain Reaction
Antibody titer
Middle Aged
Titer
Treatment Outcome
AcademicSubjects/MED00290
Infectious Diseases
Spike Glycoprotein
Coronavirus
RNA
Viral
Female
Antibody
Coronavirus Infections
Cohort study
Adult
Pneumonia
Viral
03 medical and health sciences
Betacoronavirus
Major Article
Humans
Pandemics
COVID-19 Serotherapy
plasma
Aged
business.industry
SARS-CoV-2
convalescent
Immunization
Passive
COVID-19
Antibodies
Neutralizing
Clinical trial
neutralizing
030104 developmental biology
Immunology
biology.protein
business
Zdroj: The Journal of Infectious Diseases
ISSN: 1537-6613
0022-1899
DOI: 10.1093/infdis/jiaa505
Popis: Background Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and their impact in patients with acute COVID-19 remains largely undetermined. We measured NAb titers in CP and in patients with acute COVID-19 before and after transfusion through the traditional Food and Drug Administration investigational new drug pathway. Methods We performed a single-arm interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 14-day period in hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection. Results NAb titers in the donor CP units were low ( Conclusions CP infusion did not alter recipient NAb titers. Prescreening of CP may be necessary for selecting donors with high titers of neutralizing activity for infusion into patients with COVID-19. Clinical Trials Registration NCT04434131.
Databáze: OpenAIRE
Externí odkaz: